Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Merck & Co., Inc. in a note issued to ...

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

The iShares Top 200 Growth ETF focuses on large-cap growth stocks but uses high price-to-book ratios, which I believe is a ...

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...

If you're interested in broad exposure to the Small Cap Value segment of the US equity market, look no further than the JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), a passively managed ...

US stocks finished lower on Friday, with the S&P 500 pulling back from record highs, as investors reacted to data showing that private sector growth slowed to a nine-month low.

Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical company’s chief business officer, to chief operating officer, and ...